FMX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
FMX is a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock shows a constructive technical setup, improving fundamentals in the latest quarter, and a generally supportive analyst backdrop. With no negative news flow, no notable insider or hedge fund selling, and neutral-to-positive options sentiment, this looks like a reasonable long-term entry at the current pre-market price of 119.91.
FMX's trend is bullish. The stock is trading above key moving averages with SMA_5 > SMA_20 > SMA_200, which signals a sustained uptrend. MACD histogram is positive at 0.451, though slightly contracting, suggesting momentum is still positive but not accelerating. RSI_6 at 59.743 is neutral-to-healthy, not overbought. Price is currently above the pivot level of 117.672 and below R1 at 122.546, leaving room for upside toward resistance near 122.55 and 125.56. Overall, the chart favors a buy for a long-term investor entering now.
revenue rose 15.61% YoY", "Net income increased 73.79% YoY, showing strong profitability improvement", "EPS grew 85.71% YoY", "Barclays, JPMorgan, and UBS all raised price targets recently", "No recent negative news in the last week", "No significant insider selling and hedge funds are neutral", "Bullish moving average alignment supports the current uptrend"]
["Gross margin declined 4.88% YoY in the latest quarter", "MACD histogram is positive but contracting, so momentum is not strengthening sharply", "Analyst ratings are mixed overall, with Barclays and JPMorgan keeping neutral/equal-weight views despite higher targets", "No recent news catalysts to drive an immediate breakout", "Stock trend model suggests a weak short-term pullback probability over the next week"]
In 2025/Q4, FMX posted solid growth across the top and bottom line. Revenue increased to 12.03 billion, up 15.61% YoY, net income rose 73.79% YoY to 465.25 million, and EPS climbed 85.71% YoY to 0.13. This is a strong earnings quarter, though gross margin declined to 41.54%, down 4.88% YoY, indicating some pressure on profitability efficiency despite strong operating growth.
Analyst sentiment has improved over the last few months. Barclays raised its target to $125 from $118 and maintained Equal Weight, JPMorgan raised to $117 from $98 and kept Neutral, and UBS raised to $122 from $109 and kept Buy. Earlier Barclays also lifted targets to $118 and then $116. The overall Wall Street view is mixed but improving: pros include rising price targets and solid earnings execution; cons include mostly Neutral/Equal Weight stances from major banks, which means analysts see upside but are not aggressively bullish.
